A multicentre, controlled Phase IIb study of Allogeneic osteoblastic cell (ALLOB) for the treatment of difficult fractures.
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Allogeneic osteoblastic cell therapy Bone Therapeutics (Primary)
- Indications Fracture
- Focus Therapeutic Use
- 06 Nov 2019 According to a Bone Therapeutics media release, the company has obtained scientific advice from European regulatory authorities to support the submission of the clinical trial application for the conduct of the trial. The first clinical batches of ALLOB are now being produced and stored as a cryopreserved stock to be used in the trial.
- 14 Sep 2018 According to a Bone Therapeutics media release, the company expects to submit the Clinical Trial Application (CTA) for the trial in second half of 2019.
- 24 Jan 2018 New trial record